Related Experiment Video
Updated: Jun 27, 2026
16:56
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
17.2K
Intranasal Immunization with Chitosan-PLGA-rOmp22 Protects Against Multidrug-Resistant Acinetobacter
Ning Yang1, Jianpeng Xue2, Runlu Zhou1
1Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, China.
ACS Infectious Diseases
|July 1, 2025
Summary
A novel nanovaccine, Chitosan-PLGA-rOmp22, offers protection against Acinetobacter baumannii infections. Intranasal immunization with this nanovaccine elicits robust immune responses and prevents infection.
Area of Science:
- Microbiology
- Immunology
- Nanotechnology
Background:
- Acinetobacter baumannii infections pose a significant clinical challenge due to the rise of extensively drug-resistant strains.
- Vaccination is a critical strategy for preventing and controlling A. baumannii infections.
- Developing effective vaccines against multidrug-resistant bacteria is a global health priority.
Purpose of the Study:
- To construct and evaluate a novel nanovaccine, Chitosan-PLGA-rOmp22 (CS-PLGA-rOmp22), for Acinetobacter baumannii.
- To assess the immunogenicity and protective efficacy of intranasal immunization with the CS-PLGA-rOmp22 nanovaccine.
- To investigate the mechanism of action of the nanovaccine in inducing immune responses.
Main Methods:
- Construction of the Chitosan-PLGA-rOmp22 (CS-PLGA-rOmp22) nanovaccine.
- Intranasal immunization of BALB/c mice with the CS-PLGA-rOmp22 nanovaccine.
- Evaluation of local mucosal and systemic immunity.
- Assessment of protection against Acinetobacter baumannii challenge.
- In vitro studies on dendritic cell (DC) maturation and activation.
- Comparison of intranasal and subcutaneous immunization routes.
Main Results:
- Intranasal immunization with CS-PLGA-rOmp22 induced long-lasting local mucosal and systemic immunity in mice.
- Mice immunized intranasally with the nanovaccine demonstrated resistance to Acinetobacter baumannii challenge.
- The CS-PLGA-rOmp22 nanovaccine effectively penetrated the nasal mucosa and promoted dendritic cell maturation and activation.
- The immunoprotective effect of intranasal vaccination was comparable to that of subcutaneous immunization.
Conclusions:
- The CS-PLGA-rOmp22 nanovaccine is a promising candidate for preventing Acinetobacter baumannii infections.
- Mucosal administration via intranasal immunization provides effective protection against A. baumannii.
- This nanovaccine strategy holds potential for controlling infections caused by drug-resistant bacterial strains.
